Medivie Therapeutic (Israel) Performance
| MDVI Stock | ILA 80.40 0.20 0.25% |
On a scale of 0 to 100, Medivie Therapeutic holds a performance score of 8. The company secures a Beta (Market Risk) of 1.63, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Medivie Therapeutic will likely underperform. Please check Medivie Therapeutic's semi deviation, coefficient of variation, jensen alpha, as well as the relationship between the downside deviation and standard deviation , to make a quick decision on whether Medivie Therapeutic's current price movements will revert.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Medivie Therapeutic are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Medivie Therapeutic sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 7.8 M | |
| Total Cashflows From Investing Activities | -4.2 M |
Medivie |
Medivie Therapeutic Relative Risk vs. Return Landscape
If you would invest 6,510 in Medivie Therapeutic on January 19, 2024 and sell it today you would earn a total of 1,530 from holding Medivie Therapeutic or generate 23.5% return on investment over 90 days. Medivie Therapeutic is generating 0.5289% of daily returns and assumes 4.9257% volatility on return distribution over the 90 days horizon. Simply put, 43% of stocks are less volatile than Medivie, and 90% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Medivie Therapeutic Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medivie Therapeutic's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Medivie Therapeutic, and traders can use it to determine the average amount a Medivie Therapeutic's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1074
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MDVI | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.93 actual daily | 43 57% of assets are more volatile |
Expected Return
| 0.53 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Medivie Therapeutic is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medivie Therapeutic by adding it to a well-diversified portfolio.
Medivie Therapeutic Fundamentals Growth
Medivie Stock prices reflect investors' perceptions of the future prospects and financial health of Medivie Therapeutic, and Medivie Therapeutic fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medivie Stock performance.
| Return On Equity | -1.56 | |||
| Return On Asset | -1.09 | |||
| Operating Margin | (24.81) % | |||
| Current Valuation | 47.6 M | |||
| Shares Outstanding | 2.88 M | |||
| Price To Book | 10.59 X | |||
| Price To Sales | 71.11 X | |||
| Revenue | 491 K | |||
| EBITDA | (5.16 M) | |||
| Cash And Equivalents | 4.15 M | |||
| Cash Per Share | 1.44 X | |||
| Total Debt | 3.19 M | |||
| Debt To Equity | 0.85 % | |||
| Book Value Per Share | 1.32 X | |||
| Cash Flow From Operations | (3.88 M) | |||
| Earnings Per Share | (4.53) X | |||
| Total Asset | 12.19 M | |||
| Retained Earnings | (121 M) | |||
About Medivie Therapeutic Performance
To evaluate Medivie Therapeutic Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Medivie Therapeutic generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Medivie Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Medivie Therapeutic market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Medivie's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Medivie Therapeutic Limited develops and markets dental devices. Medivie Therapeutic Limited was founded in 2012 and is based in Hemel Hempstead, the United Kingdom. MEDIVIE THERP is traded on Tel Aviv Stock Exchange in Israel.Things to note about Medivie Therapeutic performance evaluation
Checking the ongoing alerts about Medivie Therapeutic for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Medivie Therapeutic help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medivie Therapeutic appears to be risky and price may revert if volatility continues | |
| The company has accumulated 3.19 M in total debt with debt to equity ratio (D/E) of 0.85, which is about average as compared to similar companies. Medivie Therapeutic has a current ratio of 0.64, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Medivie Therapeutic until it has trouble settling it off, either with new capital or with free cash flow. So, Medivie Therapeutic's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medivie Therapeutic sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medivie to invest in growth at high rates of return. When we think about Medivie Therapeutic's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 491 K. Net Loss for the year was (6.59 M) with loss before overhead, payroll, taxes, and interest of (603 K). | |
| Medivie Therapeutic has accumulated about 4.15 M in cash with (3.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.44. | |
| Roughly 72.0% of Medivie Therapeutic outstanding shares are owned by corporate insiders |
- Analyzing Medivie Therapeutic's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medivie Therapeutic's stock is overvalued or undervalued compared to its peers.
- Examining Medivie Therapeutic's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medivie Therapeutic's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medivie Therapeutic's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medivie Therapeutic's stock. These opinions can provide insight into Medivie Therapeutic's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medivie Therapeutic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Medivie Stock analysis
When running Medivie Therapeutic's price analysis, check to measure Medivie Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medivie Therapeutic is operating at the current time. Most of Medivie Therapeutic's value examination focuses on studying past and present price action to predict the probability of Medivie Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medivie Therapeutic's price. Additionally, you may evaluate how the addition of Medivie Therapeutic to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |